John Tsai joins Daiichi Sankyo as global head of R&D
Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026.
Dr Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an executive partner responsible for starting new biotech companies based on scientific innovation and also driving execution across several biotech companies focused on oncology, cardiovascular and kidney disease therapeutic areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze